KRAS and gastric adenocarcinoma: In TCGA data of gastric adenocarcinoma [5], the prevalence of TP53, CDH1, KRAS, and APC mutations including amplification and deep deletion was 48%, 11%, 16%, and 18%, which is different from our data of 58.7%, 26.1%, 21.7%, and 13.0%.